Update shared on 19 Nov 2025
Analysts have raised their price target for Neogen modestly, citing improved profit margin projections and a slightly lower expected future price-to-earnings ratio as key factors behind the adjustment.
What's in the News
- Neogen appointed Bryan Riggsbee as its new Chief Financial Officer, effective November 3, 2025. David Naemura, the outgoing CFO, will remain through the year to ensure a smooth transition. (Key Developments)
- The company reaffirmed its earnings guidance for fiscal year 2026, projecting revenue between $820 million and $840 million. (Key Developments)
- Neogen renewed its partnership with the United States Equestrian Federation to continue providing support and educational materials on equine botulism prevention and treatment. (Key Developments)
- David Naemura, current CFO, announced his intention to resign. There were no disagreements regarding the company's operations or financial controls. He will assist in onboarding his successor. (Key Developments)
Valuation Changes
- The discount rate has risen slightly from 8.75% to 8.96%.
- The revenue growth forecast remains virtually unchanged, holding at approximately -0.55%.
- The net profit margin is projected to rise moderately from 12.64% to 13.39%.
- The future price-to-earnings (P/E) ratio has declined from 20.76x to 19.71x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.